5 Result: Nikola
Mesoblast Faces Regulatory Setback; Nikola's Earnings: A Preview
August 04th, 2023
Mesoblast Limited (Nasdaq: MESO) has announced the receipt of a comprehensive response from the US Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) resubmission for remestemcel-L. The FDA's response stipulates the . Read more
Market Buzz: Nikola's Romeo Power Assets Transfer, Impel Pharma's Patent Win
July 05th, 2023
Romeo Power, Inc., a subsidiary of Nikola Corporation (Nasdaq: NKLA), transferred ownership of its tangible and intangible assets to SG Service Co., LLC, acting as Assignee for the Benefit of Creditors of Romeo, as per a regulatory filing with the SE. Read more
Nikola Reveals Strategic Moves, MorphoSys Surges on Positive PT Revisions
June 16th, 2023
Nikola Corporation (Nasdaq: NKLA) has provided a progress update on its business optimization efforts, which aim to streamline operations and reduce cash spend. As part of these initiatives, the company conducted a thorough review of its organization. Read more
Nikola Strikes Back; Analysts Bullish on Jabil
June 16th, 2023
In a regulatory filing with the SEC, Nikola Corporation (Nasdaq: NKLA) has responded to a recent social media post by its former CEO, Trevor Milton, stating that it misstates the facts. According to the company, since Milton's departure in September . Read more
Celsius Holdings Upgraded, Nikola Downgraded, and Electronic Arts Receives Price Target Boost: Market Reactions Unfold
May 10th, 2023
Celsius Holdings, Inc. (Nasdaq: CELH) has received a notable upgrade from BofA Securities, shifting its rating from Neutral to Buy. Alongside the upgrade, BofA Securities has raised the price target for CELH to $125 from $98. This positive developmen. Read more
Want To Find Some News?
News By Industries
Recent Post
-
Johnson & Johnson, Charles Schwab, Halliburton: Earnings Preview
January 18th, 2026Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026




Member Login